Compare SONO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | ANIP |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2018 | 1999 |
| Metric | SONO | ANIP |
|---|---|---|
| Price | $16.25 | $79.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.67 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.3M | 346.2K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.52 | ★ 1.28 |
| Revenue | ★ $1,443,276,000.00 | $206,547,000.00 |
| Revenue This Year | $5.04 | $21.01 |
| Revenue Next Year | $6.53 | $17.59 |
| P/E Ratio | ★ $30.23 | $58.77 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $9.97 | $59.89 |
| 52 Week High | $19.82 | $99.50 |
| Indicator | SONO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 51.33 |
| Support Level | $15.83 | $79.69 |
| Resistance Level | $17.81 | $83.61 |
| Average True Range (ATR) | 0.59 | 2.53 |
| MACD | 0.06 | -0.53 |
| Stochastic Oscillator | 76.21 | 62.49 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.